After three years of a bull market, many investor portfolios are starting to feel the strain—think of it as the sniffles before a full-blown cold hits. 👀
Hey, Bow Tai Nation! Joseph Hog here. I may not be a doctor, but I can tell you your portfolio might be under some serious stress. From reviewing portfolios in our community, I’ve noticed something: after tech stocks skyrocketed over 150% in the past three years, many investors now have more than half of their money tied up in tech and growth stocks.
And while that strategy has been great so far, it’s like running your portfolio with high blood pressure—one shock to the market and it could suffer a heart attack. 💥
I’m not saying a crash is coming… but when it does, you’re going to need some safety stocks to weather the storm. And that’s where healthcare stocks shine.
Here are five healthcare stocks that could stabilize your portfolio while still giving you growth. Let’s dive in! 👇
1️⃣ Medtronic (MDT) – Medical Devices
✅ Up 18% last year
✅ Dividend: 2.9%
Medtronic is a powerhouse in cardiovascular, neuroscience, and surgical markets, pulling in $30B of $99B total revenue. With $123B in scale, they’re constantly innovating and rolling out new products.
Upcoming catalysts include:
Ablation solutions adding $1B in revenue
Launches of three new products
Spin-off of its diabetes unit, potentially boosting margins
Analysts are bullish too: the high target gives 24% upside, even the low is 6%. Not bad for a stock that’s also a dividend payer! 💰
2️⃣ AbbVie (ABBV) – Pharma Giant
✅ Up 23% last year
✅ Dividend: 3%
AbbVie dominates immunology, oncology, and neuroscience, moving from older blockbusters like Humira to high-growth drugs like Skyrizi and Rinvoq—expected to generate $31B by 2027.
Analysts see 17% upside on average over the next year, with earnings projected to jump 36% next year. Even with short-term challenges, AbbVie is a long-term winner. 🚀
3️⃣ Sigma Health Insurance (CI) – Steady Rebound Potential
✅ Down 3% last year
✅ Dividend: 2%
Insurance companies may get bad press around elections, but Sigma has consistent earnings growth at 13% annually over the past decade. Analysts see 23–39% upside potential, making it a strong “buy the dip” candidate. 🩺
4️⃣ Eli Lilly (LLY) – Metabolic & Diabetes Leader
✅ Up 35% last year, 483% in 5 years
✅ Dividend: 0.5%
Lilly’s dominance in weight-loss drugs and diabetes is staggering. Zepbound controls 63% of the branded anti-obesity prescription market, and upcoming drugs could push revenue to $76B. Earnings are expected to jump 150% over 2 years.
It’s not cheap, but if growth continues, this is one of the most exciting healthcare plays out there. 💊💥
5️⃣ iShares Biotechnology ETF (IBB) – 1 Fund, 250+ Companies
✅ Up 27% last year
Picking individual biotech winners is tough—FDA approvals can make or break a stock overnight. That’s why IBB is perfect for diversification. It holds over 250 biotech and pharmaceutical companies, from giants like Gilead to smaller innovators like CRISPR Therapeutics.
For broad exposure to the entire sector, you can also check out the Healthcare Sector ETF (XLV)—covering the 60 largest healthcare companies.
Healthcare stocks aren’t just growth—they’re safety nets in volatile markets. They sell things people need, no matter the economy, like cholesterol meds and treatments.
📈 Right now, investors are already rotating into healthcare: the sector is up 10% in the last 3 months, making it one of the top-performing groups.
🚀 Take Action Now
Want to invest in a diversified healthcare ETF without picking individual stocks? Check out Moomoo’s ETF options and get your portfolio ready for 2026:
👉 Invest in Healthcare ETFs on Moomoo
Protect your portfolio. Stay healthy. And ride the next growth wave with confidence. 💪
#HealthcareStocks #InvestSmart #ETFs #StockMarket2026 #Moomoo
